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Abstract
Background: The purposes of the study were to compare serum total cortisol (STC), salivary cortisol (SaC) and
calculated free cortisol (cFC) levels at baseline and after the adrenocorticotrophic hormone (ACTH) stimulation test
in patients with severe sepsis (SS) and determine the suitability of use of SaC and cFC levels instead of STC for the
diagnosis of adrenal insufficiency (AI) in patients with SS. And secondary aims of this study were to compare these
parameters in patients with SS with healthy controls and check their effects on survival status of the patients.
Methods: Thirty patients with SS (15 men and 15 women) were compared with 16 healthy controls. Low-dose
(1 μg) ACTH stimulation test was performed to the patients on the first, seventh and 28th days of diagnosis of SS,
but in control group, 1 μg ACTH stimulation test was performed only once. STC, SaC and cFC levels were measured
during ACTH stimulation test.
Results: Patients were categorized as having low or high baseline STC according to a cut-off level of 10 μg/dL. In
high STC group, baseline and peak SaC levels were found to be 2.3 (0.2–9.0) and 3.4 (0.5–17.8) μg/dL on D1 and 1.1
(0.8–4.6) and 2.6 (1.3–2.9) μg/dL on D7, respectively. In the control group, baseline and peak SaC levels were 0.4
(0.1–1.4) and 1.1 (0.4–2.5) μg/dL, respectively. Baseline and peak SaC levels after ACTH stimulation were found to be
higher in high STC group than in controls, but they were found to be similar in low STC and control groups. In
high STC group, cFC levels were 0.3 (0.1–0.3) and 0.4 (0.3–0.7) μg/dL on D1 and 0.2 (0.1–0.3) and 0.4 (0.1–0.7) μg/dL
on D7, respectively. In the control group, baseline and peak cFC levels were 1.7 (0.4–1.9) and 1.8 (1.0–6.6) μg/dL,
respectively. cFC levels were found to be lower in patients with SS subgroups than in the control group. Baseline
and stimulated STC, SaC and cFC levels did not differ according to the survival status. SaC, cFC and STC levels were
found to be correlated with each other.
Conclusions: SS is associated with increased SaC, but decreased cFC levels when baseline STC is assumed to be
sufficient. When STC level is assumed to be insufficient, SaC levels remain unchanged, but cFC levels are decreased.
Lower STC levels is not associated with increased mortality in patients with SS. More data are needed in order to
suggest the use of SaC and cFC instead of STC.
Trial registration: ClinicalTrials.gov No: NCT02589431
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Background
In stress-free people, cortisol is secreted in diurnal pat-
tern. Any type of acute illness or trauma results in loss
of the diurnal variation of cortisol secretion [1]. In case
of a critical illness, organism needs to maintain adequate
cortisol levels to cope with the illness. Cortisol response
to such an illness is one of the factors that determines sur-
vival [2]. Lower or higher levels of serum total cortisol
(STC) levels than expected were reported to be closely re-
lated to survival status [3]. As a kind of critical illness, sep-
sis may lead to major changes in hypothalamo-pituitary-
adrenal (HPA) axis that causes challenges in the evalu-
ation of its functions in those patients [4, 5].
Relative adrenal insufficiency (RAI), or critical illness-
related corticosteroid insufficiency (CIRCI), is a form of
adrenal insufficiency (AI) in critically ill patients whose
cortisol levels are inadequate for the severe stress response
they experience [6]. The diagnosis of CIRCI and the indi-
cations for corticosteroid therapy in critical illness (CI) are
still controversial [3, 6–10]. Baseline or random STC
levels, cortisol increment after adrenocorticotrophic hor-
mone (ACTH) stimulation test (delta cortisol), free corti-
sol (FC) levels, or other markers presenting FC, or a
combination of these tests have been proposed as diagnos-
tic tests for CIRCI [4, 8–11].
Annane et al. have reported a delta cortisol of less than
9 μg/dL or a random cortisol of less than 10 μg/dL as
the best predictors of AI in patients with severe sepsis
(SS) and septic shock [9]. But, in critically ill patients,
since the adrenal glands might already be maximally
stimulated, baseline cortisol levels may be higher than
ACTH-stimulated serum cortisol levels [4, 5]. For this
reason, some authors suggest measuring random serum
cortisol levels at any time of the day regardless of corti-
sol diurnal rhythm [6, 9].
More than 90 % of circulating cortisol is predomin-
antly bound to not only cortisol binding globulin (CBG)
but also albumin [12]. Thus, in the presence of both hy-
poalbuminemia and decreased CBG levels, the ratio of
bound to free cortisol levels can be altered. In this situ-
ation, measurement of FC becomes more important.
Since direct FC measurement is time consuming and
non-automated, some indirect methods to determine FC
levels had been introduced such as Coolens’ method [12,
13]. In patients with CI, the synthesis of CBG and albu-
min is reduced leading to overestimation of AI if we
only use STC levels. Since some studies demonstrated
that salivary cortisol (SaC) reflects free or unbound
plasma cortisol levels, this method is used more often in
clinical studies [14–19]. STC and SaC levels at baseline
and after ACTH stimulation had been used in some
studies in patients with CI [17, 18].
The aims of the present study were to compare STC,
SaC and calculated free cortisol (cFC) levels at baseline
and after the ACTH stimulation test in patients with SS
and determine the suitability of SaC and cFC levels in-
stead of STC for the diagnosis of AI in patients with SS.
And secondary aims of this study were to compare these
parameters in patients with SS with healthy controls and
check their effects on survival status of the patients.
Patients and methods
The study was registered to Clinical Trials. Clinical trial
Gov No: NCT02589431.
Patients
Patients meeting the American College of Chest Physi-
cians (ACCP)/Society of Critical Care Medicine (SCCM)
consensus definition of SS [20] were enrolled from the In-
ternal Medicine Intensive Care Unit (ICU) of our hospital.
The study was approved by the Local Ethics Committee.
Informed consent was obtained from all volunteers or
their first-degree relatives. Exclusion criteria were the
presence of malignancy, history of corticosteroid expos-
ure, and also presence of any disease that could affect
HPA axis. We also excluded the patients who have any
visible bleeding in their oral cavity.
Thirthy patients with SS (15 men and 15 women) and
16 (8 men and 8 women) healthy controls were included
in the study. The first 24 h of diagnosis of SS was shown
as day (D) 1. Baseline hormone tests were obtained espe-
cially in the morning between 08.00–09.00 a.m. within
24 h after the symptoms of SS were detected (D1). HPA
axis was evaluated by baseline STC, SaC and cFC levels,
and STC, SaC and cFC response to low-dose (1 μg)
ACTH stimulation test. ACTH stimulation test was also
performed in the morning. The patients who were alive
and accepted to continue in the participation of the
study were evaluated again on seventh (D7) and 28th
(D28) days of SS.
While the patients were treated for SS by his/her own
physician in ICU, they were evaluated for the presence/
absence of (relative) AI concurrently. AI was suspected/
considered clinically in the presence of hemodynamic in-
stability and/or hyponatremia-hyperkalemia. Patients,
who were determined as AI by their treating physician
and administered glucocorticoid therapy, were excluded
from the study.
Apart from routine daily evaluations, blood samples
were obtained from all the patients in accordance with
the study protocol. All the blood and saliva samples
were stored at −80 °C and assayed after the study proto-
col finished. Thus, although this is a prospective study,
samples were analysed retrospectively.
Low-dose ACTH stimulation test was performed on
D1, D7 and D28 as described previously [21]. cFC levels
were estimated by Coolens’ equation [13]. Blood and sal-
iva samples were obtained before and 30 and 60 min
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after ACTH injection. STC, CBG and SaC levels were
measured during the ACTH stimulation tests. We have
used baseline and peak hormone levels after ACTH
stimulation test to compare the groups. No adverse
events were reported during the tests. Between D1–D7
of the study, only baseline STC, SaC and cFC levels were
obtained. Acute Physiology and Chronic Health Evalu-
ation (APACHE) II score [22] and Sequential Organ Fail-
ure Assessment (SOFA) score [23] were calculated for
each patient on D1, D7 and D28. Data were compared
with 16 healthy controls. Patient enrollment is summa-
rized in Fig. 1.
Irrespective of the decision of the treating physician
on the diagnosis of AI, we have categorized the patients
retrospectively as low or high baseline STC group ac-
cording to the baseline STC cut-off level of 10 μg/dL on
D1, D7 and D28.
Assays
STC levels were measured by RIA method (Immuno-
tech; Prag, Czech Republic) with an intraassay coefficient
of variation 5.1 % and interassay coefficient of variation
9.2 %. Serum CBG concentrations were analysed with
RIA (BioSource Europe S.A., Nivelles, Belgium). Intraas-
say and interassay coefficients of variation were 3.9 and
5.5 %, respectively. The Coolens' method was used to
calculate serum FC concentration: FC2K (1 +N) + FC [1
+N + K (G − T)] − T = 0, where K = 3 × 10−7 M−1, M = af-
finity of CBG to cortisol at 37 °C, G = CBG, FC = free
cortisol, T = cortisol and N = ratio of albumin bound to
FC (1.74). FC was calculated as follows: FC ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Z2 þ T1þNð ÞK −Z
q
, and Z ¼ 12K þ G−T2 1þNð Þ [13]. Saliva sam-
ples were collected, stored and analysed as described
previously [24]. SaC was measured by using high-
sensitivity enzyme immunassay (EI) kit (Salimetrics® Inc,
State College, PA, USA), according to the manufacturer’s
instructions [15, 17]. The interassay coefficient of vari-
ation over the range of low to high values varied from
5.7 to 6.8 %, whereas the respective intraassay coeffi-
cients of variation were 3.2 and 6.3 % [15].
Statistical analysis
All statistical analysis were done by Statistical Package for
Social Sciences (SPSS for Windows, version 15; Chicago;
IL). Normal distribution of the data were tested by
Shapiro-Wilk test. Since the data were not distributed
normally, statistical analysis was done by nonparametric
tests. The hormone results are presented as median, mini-
mum and maximum levels. Statistical significance was set
at p value less than 0.05.
Fig. 1 Patient enrollment
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Results
There were no statistical difference between the mean
ages of the patients of SS and the control group (61.7 ±
14.7 (range 23–82) and 58.7 ± 4.1 (range 51–64) years,
respectively).
Among patients diagnosed with SS, the infection origi-
nated from the lung in 12 patients (40 %) (pneumonia),
blood in 4 patients (13 %), urine in 8 patients (27 %),
gastrointestinal tract in 4 patients (13 %) and skin and
soft tissue in 2 patients (7 %). Mean leukocyte count of
SS patients was 12,940 ± 7502/μL.
Comorbid conditions in these 30 SS patients included
type 2 diabetes mellitus (DM) in 6 patients (20 %), coron-
ary heart disease in 11 patients (37 %) and chronic ob-
structive pulmonary disease (COPD) in 4 patients (10 %).
Nine patients (30 %) did not have any comorbidity. No re-
markable comorbidity was present in control subjects.
Among 21 patients with comorbidities, 5 were using
metformin, 2 were using metformin and gliclazide, 6
were using angiotensin converting enzyme inhibitors or
angiotensin II receptor blockers and 1 was using an
angiotensin II receptor blocker and a beta blocker com-
bination therapy before development of SS. All of the
patients with COPD were using short-acting beta-2 ago-
nists, and none of them was using inhaled corticoste-
roids. Due to hypotension, the antihypertensive drugs
were not administered to patients during SS. The pa-
tients with DM were followed with subcutaneous insulin
treatment, and treatment regimens other than glucocor-
ticoids inhaled treatments were administered to patients
with COPD.
At the onset of SS, all 30 patients were found to have
reduced blood pressure (100 %) and additionally
hypothermia occurred in 5 patients (17 %), hyperkalemia
in 2 patients (7 %) and hyponatremia in 4 patients
(13 %). Growth of microorganisms was observed in body
fluid cultures in 22 patients (%73) and 10 patients (33 %)
required vasopressor infusions. A total of 4 patients
(13 %) were administered glucocorticoid therapy accord-
ing to the judgement of following physician. These 4 pa-
tients were excluded from further analysis in the study
after steroid administration.
Patients were categorized as low or high STC group
according to their baseline STC (low if STC <10 μg/dL,
high if STC ≥10 μg/dL [9].
Thirty patients were included in the study on D1 and
11 patients were defined as low STC according to their
baseline STC levels on D1. Low STC group had delta
STC levels <9 μg/dL and peak STC levels <21 μg/dL on
D1. Not only baseline STC but also peak STC, peak SaC
and basal and peak cFC levels were also found to be sig-
nificantly lower in patients with low STC group. Baseline
and stimulated CBG levels on D1 were not different in
two groups (Table 1).
All of 5 patients died on D1 had high STC levels (41,
21, 25, 32, and 31 μg/dL, respectively). Five of 11 pa-
tients in low STC group died and 6 survived until D7.
Among 6 patients who survived until D7, 1 patient had
baseline STC levels 8.4 and 12.4 μg/dL on D1 and D7,
respectively. The remaining 5 patients with low STC on
D1 had also low STC on D7. Newly onset low STC levels
were present in 5 patients on D7. Baseline cFC levels
were also found to be lower in low STC group (Table 1).
Baseline or peak SaC and cFC levels were not found to
be different in low or high STC groups (Table 1).
No marked difference was observed between low or
high STC groups in means of albumin values and APA-
CHE II and SOFA scores. However, albumin levels were
significantly lower compared to healthy group irrespect-
ive of the baseline STC (p < 0.01). Groups were com-
pared at the end of D7 and D28 with respect to serum
albumin levels obtained on D1 and D7 depending on
survival. Serum albumin values did not differ between
SS subgroups. Mean APACHE II score was 21 (min 7,
max 37) on D1 and 12 (min 7, max 29) on D7 among
survivors and 32 (min 16, max 40) on D1 and 33 (min
25, max 36) on D7 among non-survivors (p < 0.01).
Mean SOFA score was 6 (min 1, max 12) on D1 and 4
(min 1, max 6) on D7 among survivors and 11 (min 3,
max 21) on D1 and 13 (min 8, max 14) on D7 among
non-survivors (p < 0.01).
Hormone levels between D1–D7 were compared in
patients with SS who have survived or not until D7. On
D5 and D7, baseline STC and cFC levels and, on D1,
baseline STC and baseline and peak cFC levels were
found to be lower in patients who have survived. There
were no differences between SaC and CBG levels of the
patients who have survived or not (Table 2). The pa-
tients with low baseline STC on D1 (n = 11) were di-
vided into two groups according to their survival status
until D7. Baseline and stimulated STC, SaC and cFC
levels were not significantly different in patients who
have survived or not. Similarly, if 19 patients with high
baseline STC on D1 were divided into two groups ac-
cording to their survival status until D7, baseline and
stimulated STC, SaC and CFC levels were not found to
be different in patients who have survived or not (data
not shown).
In total, 11 patients died before D7, 3 patients were
treated with glucocorticoid between D1 and D7 (and 2
of them died before D7); 5 patients died before D28, 1
was given glucocorticoid between D7 and D28. At the
end of 28 days, 8 patients were alive.
Nineteen patients had high STC on D1, 3 of them
were given glucocorticoids (2 died), 6 of them died, 2 of
them left the study and 8 were alive at the end of 7 days.
Four patients had high STC on D7, 2 died, 1 were given
glucocorticoid and 1 were alive at the end of 28 days.
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Table 1 Baseline and peak CBG, cFC, SaC and STC levels on D1 and D7
Day of the study D1 D7 Healthy p1 p2 p3 p4 p5 p6 p7 p8
All SS patients SS with high STC SS with low STC All SS patients SS with high STC SS with low STC
n 30 19 11 14 4 10 16
STC (μg/dL) Baseline 13.7 (3.1–53.2) 18.7 (10.4–53.2) 8.2 (3.1–9.4) 7.6 (0.4–13.9) 12.4 (12.0–13.9) 6.5 (0.4–9.6) 14.3 (4.3–20) 0.13 <0.01 <0.01 <0.01 <0.01 0.01 0.67 0.03
Peak 20.3 (7.4–52.0) 31.0 (14.1–52.0) 11.0 (7.4–20.6) 12.7 (4.0–25.0) 18.9 (8.3–25.0) 12.4 (3.9–21.4) 27 (15.2–41.4) 0.64 <0.01 0.27 <0.01 <0.01 0.24 0.02 <0.01
SaC (μg/dL) Baseline 1.9 (0.2–9.0) 2.3 (0.2–9.0) 0.9 (0.2–2.9) 0.7 (0.3–4.6) 1.1 (0.8–4.6) 0.6 (0.3–3.0) 0.4 (0.1–1.4) <0.01 0.15 <0.01 0.09 0.04 0.07 0.06 0.72
Peak 2.2 (0.5–17.8) 3.4 (0.5–17.8) 1.9 (0.6–4.2) 1.7 (0.2–4.0) 2.6 (1.3–2.9) 1.5 (0.2–4.0) 1.1 (0.4–2.5) <0.01 0.02 <0.01 0.11 0.37 0.39 0.01 0.14
cFC (μg/dL) Baseline 0.5 (0.1–1.9) 0.7 (0.4–1.9) 0.3 (0.1–0.3) 0.3 (0.1–0.5) 0.4 (0.4–0.5) 0.2 (0.1–0.3) 0.7 (0.4–1.9) 0.48 <0.01 <0.01 <0.01 <0.01 0.01 0.65 <0.01
Peak 0.71 (0.3–1.9) 1.1 (0.5–1.9) 0.4 (0.3–0.7) 0.4 (0.1–0.9) 0.7 (0.3–0.9) 0.4 (0.1–0.7) 1.8 (1.0–6.6) <0.01 <0.01 <0.01 <0.01 <0.01 0.24 0.89 0.12
CBG (μg/dL) Baseline 0.3 (0.1–0.6) 0.3 (0.1–0.6) 0.2 (0.1–0.4) 0.3 (0.2–0.5) 0.4 (0.3–0.4) 0.3 (0.2–0.5) 0.5 (0.3–0.8) <0.01 0.12 <0.01 <0.01 <0.01 0.94 <0.01 <0.01
Peak 0.3 (0.1–0.5) 0.3 (0.1–0.5) 0.3 (0.1–0.5) 0.4 (0.1–0.5) 0.3 (0.2–0.4) 0.4 (0.1–0.5) 0.6 (0.4–0.9) <0.01 0.6 <0.01 <0.01 <0.01 0.35 <0.01 <0.01
Abbreviations: D1 first day of severe sepsis, n number of the subjects, STC serum total cortisol, SaC salivary cortisol, cFC calculated free cortisol, CBG cortisol binding globulin, p1 belongs to comparison between
hormon levels of the patients with severe sepsis on D1 and healthy control, p2 belongs to comparison between patients who have basal STC ≥ or <10 μg/dL on D1, p3 belongs to comparison between patients with
severe sepsis who have baseline STC ≥10 μg/dL on D1 and healthy control, p4 belongs to comparison between patients with severe sepsis who have baseline STC <10 μg/dL on D1 and healthy control, p5 belongs to
comparison between hormone levels of the patients with severe sepsis on D7 and healthy control, p6 belongs to comparison between patients who have baseline STC ≥ or <10 μg/dL on D7, p7 belongs to












Table 2 Differences between STC, SaC, cFC and CBG levels of the patients who have survived or not
Days Number Survival STC (μg/dL) SaC (μg/dL) cFC (μg/dL) CBG (μg/dL)
Baseline Peak Baseline Peak Baseline Peak Baseline Peak
D1 30 Alive 9.4 (3.1–25.8) 14.3 (7.4–46.9) 1.0 (0.2–7.5) 2.0 (0.6–15.0) 0.3 (0.1–0.9) 0.5 (0.3–1.7) 0.3 (0.1–0.6) 0.4 (0.2–0.5)
Dead 21.0 (4.6–53.2) 31.0 (7.5–52.0) 2.3 (0.2–9.0) 3.4 (0.5–17.8) 0.8 (0.2–1.87) 1.1 (0.3–1.9) 0.2 (0.1–0.5) 0.3 (0.1–0.5)
D2 22 Alive 12.4 (4.9–40.9) 0.7 (0.1–3.3) 0.4 (0.2–1.4) 0.2 (0.1–0.5)
Dead 17.7 (5.6–24.8) 0.6 (0.1–5.2) 0.8 (0.3–1.5) 0.2 (0.2–0.5)
D3 20 Alive 10.2 (3.2–31.3) 0.7 (0.1–3.8) 0.3 (0.1–1.1) 0.2 (0.1–0.5)
Dead 22.8 (7.9–43.3) 0.9 (0.1–5.2) 0.8 (0.3–1.5) 0.2 (0.2–0.4)
D4 20 Alive 12.6 (3.5–22.1) 0.8 (0.1–3.0) 0.5 (0.1–0.8) 0.3 (0.1–0.4)
Dead 18.6 (3.3–50.5) 2.2 (0.2–9.4) 0.7 (0.1–1.8) 0.3 (0.1–0.4)
D5 19 Alive 11.4 (5.2–30.4) 0.8 (0.1–4.6) 0.4 (0.2–1.1) 0.3 (0.1–0.4)
Dead 20.2 (15.6–30.0) 0.7 (0.1–3.1) 0.7 (0.6–1.1) 0.2 (0.2–0.4)
D6 17 Alive 10.4 (2.1–43.0) 1.0 (0.1–4.6) 0.4 (0.1–1.5) 0.2 (0.1–0.5)
Dead 27.3 (5.6–32.6) 2.0 (0.9–4) 1.0 (0.2–1.2) 0.3 (0.1–0.4)
D7 14 Alive 6.9 (0.4–13.9) 9.9 (3.9–25.0) 0.5 (0.3–3.0) 1.7 (0.2–4.0) 0.2 (0.1–0.5) 0.4 (0.1–0.9) 0.3 (0.2–0.5) 0.4 (0.2–0.5)
Dead 8.7 (5.6–12.4) 13.3 (8.3–18.8) 0.9 (0.6–4.6) 2.4 (0.6–2.9) 0.3 (0.2–0.4) 0.5 (0.3–0.7) 0.3 (0.2–0.5) 0.3 (0.1–0.4)
p1 0.02 0.53 0.28 0.12 0.02 0.01 0.39 0.27
p2 0.08 0.64 0.57 0.56
p3 0.55 0.69 0.06 0.36
p4 0.02 0.32 0.55 0.91
p5 0.02 0.9 0.02 0.44
p6 0.3 0.2 0.3 0.5
p7 0.01 0.24 0.07 0.39 0.01 0.24 0.94 0.35
Abbreviations: STC serum total cortisol, SaC salivary cortisol, cFC calculated free cortisol, CBG cortisol binding globulin, D day of severe sepsis, p1, p2, p3, p4, p5, p6 and p7 belongs to comparisons between patients











Five of 11 patients with low STC on D1 died and 6
were alive at the end of 7 days. One of the patients with
low STC group on D1 was recovered until D7. On D7, 5
new patients with baseline STC levels lower than 10 μg/
dL were added to lower STC group (final number was
10). Three of these 10 patients with low STC value on
D7 died and 7 of them were alive at the end of 28 days.
One of the 8 patients who were alive on D28 was in high
STC group. Although 8 patients were alive, only 4 pa-
tients could participate our study on D28 of SS. The in-
dividual data of the these 4 patients on D28 are
summarized in Table 3.
When patients were divided into two groups according
to their survival status on D28, there were no differences
in hormone levels of the patients between two groups.
Only APACHE II and SOFA scores were found to be
significanly higher in patients who died.
Data of patients with SS were compared with 16
healthy people. Baseline STC, baseline and stimulated
SaC levels were significantly higher in patients with SS
with high STC than in healthy subjects. Baseline and
stimulated cFC levels were found to be higher in high
STC group than in low STC SS groups. But baseline and
stimulated cFC levels were found to be lower in patients
with high STC on D1 than control group. On D7, only
baseline cFC levels were found to be higher in patients
with high STC than in patients with low STC. Baseline
and stimulated STC and cFC levels were found to be sig-
nificantly lower in patients with low baseline STC than
in healthy people, but SaC levels were found to be simi-
lar in two groups (Table 1). Serum CBG and albumin
levels were found to be significantly lower in both SS
groups than in healthy group (Table 1).
All simultaneous baseline SaC and STC levels of pa-
tients with SS were pooled, and 145 pairs were obtained.
Similarly, all simultaneous SaC and STC responses of pa-
tients to low-dose ACTH stimulation test were also
pooled, and 48 pairs were obtained. SaC and STC were
positively correlated with each other (p < 0.01, r = 0.26 and
p < 0.01, r = 0.30, respectively, for random and stimulated
levels). SaC and cFC levels were also positively correlated
with each other (p = 0.02, r = 0.23 and p < 0.01, r = 0.53, re-
spectively, for random and stimulated levels) (Fig. 2).
Discussion
In this study, baseline STC levels were found to be
higher in high STC SS patients (suspected to have intact
HPA axis) than in healthy subjects. This finding was
supported by previous data [25, 26]. Not only baseline
STC but also peak STC, baseline and peak SaC re-
sponses after ACTH stimulation were found to be sig-
nificantly higher in high STC group than in both low
STC and control group. So, the cortisol production is in-
creased in order to cope with the severity of sepsis.
It is known that an appropriate response of HPA axis
to CI is crucial for survival; so, both very high or low re-
sponses have been associated with increased mortality
[27, 28]. In the present study, death was found to be as-
sociated with high cortisol levels. Many studies have
demonstrated increased STC levels in sepsis, and the de-
gree of the elevation is related to the severity of the ill-
ness [25–29]. Similarly, in a study by Yildiz et al., the
mean baseline plasma cortisol concentration was signifi-
cantly lower in survivors compared with non-survivors
in sepsis [25]. In another, although baseline and stimu-
lated STC levels were higher in sepsis group than their
recovery status on the 14th day of sepsis, baseline and
stimulated STC levels were not found to be related to
mortality [29]. But in the present study, baseline and
peak STC on D1 and baseline STC levels between D1–
D7 tended to be lower in patients who survived. Both
baseline and stimulated STC levels were lower in the
present study than in the study of Yildiz et al. [29]. In
their study, higher peak STC levels may be explained by
the use of higher dose of synthetic ACTH for test, but
baseline STC levels were also found to be higher. Pa-
tients group which enrolled the study by Yildiz et al. in-
cluded not only patients with SS but also sepsis [29]. So,
their study population was not homogenous. Discord-
ance between the two studies may be explained by this
scenario.
In the present study, serum CBG concentrations were
found to be lower in SS than in healthy individuals com-
patible with prior studies [13, 30]. The lower CBG levels
in sepsis can be explained by multifactorial causes such as
decreased liver synthesis of CBG, proteolytic cleavage by
neutrophil elastase, and less common genetic mutations
Table 3 Individual data of 4 patients on D28







Baseline Peak Baseline Peak Baseline Peak Baseline Peak
5 76 M 0.4 3.8 0.4 1.0 0.1 0.1 0.2 0.3 1.9 20 6 Died on D57
6 60 F 9.6 12.9 1.7 1.7 0.3 0.4 0.4 0.5 3.5 16 4 Alive
8 81 F 18.9 51.2 0.7 1.3 0.4 0.9 0.3 0.4 3.2 16 4 Alive
13 45 M 30.9 25.2 1.2 2.2 1.1 0.9 0.2 0.4 2.7 6 3 Alive
Abbreviations: STC serum total cortisol, SaC salivary cortisol, cFC calculated free cortisol, CBG cortisol binding globulin, D day of severe sepsis, M male, F female,
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, D the day after the diagnosis of severe sepsis,
GCC glucocorticoid
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[12, 30, 31]. And we have also shown that the CBG levels
did not show an increase after ACTH stimulation.
As expected, stimulated STC levels were found to be
lower in patients with SS who had low baseline STC
levels than in healthy group. cFC formula strongly de-
pends on STC, so similar tendency with STC and cFC
levels is not surprising. One of the major limitations of
the present study is that we have determined cFC levels
by using STC and CBG measurements. So, cFC strongly
reflects variations on STC and CBG levels. This explains
the lower cFC levels obtained in SS subgroups than in
the controls. If we could directly measure FC levels in
patients with SS, we could do more certain judgement
whether SaC levels better reflect or not serum FC levels.
Higher APACHE II and SOFA scores reflect worse
clinical outcome. In many studies, SOFA or both SOFA
and APACHE II scores were found to be related to mor-
tality [9, 25, 29]. In the present study, the patients who
did not survive also had higher APACHE II and SOFA
scores. Although APACHE II and SOFA scores were not
affected by the presence of low or high baseline STC
levels, they were found to be related to mortality.
There was a significant correlation between SaC and
STC and SaC and cFC. The relationship between SaC
and STC is nonlinear; after a rapid increase in STC first,
the serum CBG becomes saturated. CBG is saturated at
a STC of 16 to 18 μg/dL. After STC exceeds CBG satur-
ation, the free portion of cortisol increases [32]. It could
explain why SaC and cFC levels do not increase
simultaneously.
Conclusions
In conclusion, SS is associated with increased SaC, but
decreased cFC levels when baseline STC is assumed to
be sufficient. When STC level is assumed to be insuffi-
cient, SaC levels remain unchanged, but cFC levels are
decreased. Lower STC levels is not associated with in-
creased mortality in patients with SS. Although STC
Fig. 2 Correlations between STC, SaC and cFC in baseline and stimulated conditions
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levels are correlated with SaC and cFC levels in patients
with SS, these findings should be validated in an inde-
pendent cohort before considering SaC or cFC instead
of STC for diagnosing AI in patients with SS.
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